Storia in 4 fonti

Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio - Biogen (NASDAQ:BII

Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pipeline progress.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo9 h fa

Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio - Biogen (NASDAQ:BII

Biogen raised FY2026 guidance to $15.85–$16.85 (consensus $12.83) on Leqembi growth and $128M from Apellis acquisition. Dual strategy—M&A consolidation plus pipeline validation in MS/ALS—reflects big pharma de-risking for sustainable margins.

originale

Timeline cronologica

mercoledì 29 luglio 2026·biopharmadive.com
Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.
mercoledì 29 luglio 2026·endpoints.news
Leqembi records best quarter since launch as Biogen raises guidance
Leqembi posts record $184M in Q2, its third straight quarter of growth, as Biogen lifts full-year guidance and folds in Apellis.

Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio - Biogen (NASDAQ:BII

Confronto fonti

Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio - Biogen (NASDAQ:BII

Timeline cronologica

Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push

Leqembi records best quarter since launch as Biogen raises guidance

Biogen flips '26 guidance from expected decline to sales increase

Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push

Leqembi records best quarter since launch as Biogen raises guidance

Biogen flips '26 guidance from expected decline to sales increase

Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio - Biogen (NASDAQ:BII